anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study extends the research on the preschool home literacy environment (HLE) in the context of the family risk (FR) of reading disability (RD) by examining a multiple-deficit model of RD. A total of 1,171 six-year-old Norwegian children were assessed at school entry, the onset of formal reading instruction in Norway. Their parents completed a questionnaire regarding their own RD, education, and the HLE. The final sample after applying the inclusion criteria was 794 children and their parents. The findings suggest, first, that two HLE factors (access to print and reading-related activities) should be distinguished rather than treated as a single factor ("exposure to print") as the majority of previous studies have done. This finding suggests a three-factor HLE model that includes parents' reading interests and habits, reading-related activities, and access to print. Second, family risk of RD is related to some extent to the HLE, even after controlling for parents' education. Third, children's experiences in their home environments and their emergent literacy may not be independent of their family risk of RD. More importantly, this study highlights the potential protective role of the HLE, especially when there is a history of RD within the family. The reason is that the positive association between the HLE and children's code-related emergent literacy remains significant when controlling for family risk of RD (access to print → emergent literacy: 0.39 [0.01, 0.68], p < 0.01; reading-related activities → emergent literacy: 0.37 [0.02, 0.35], p < 0.01; parents' reading interests and habits → emergent literacy: 0.26 [0.001, 0.15], p < 0.01). This finding supports that children's emergent literacy can be improved via a modifiable, dynamic factor such as the HLE.
OBJECTIVE: The objective was to highlight the epidemiological and clinical profile of urinary incontinence in pregnant women during the first trimester and to determine their knowledge and attitudes toward this condition in Kinshasa.
METHODS: We carried out a descriptive cross-sectional study among 127 pregnant women who came for prenatal consultations in the first trimester from January to March 2022 at the LISANGA Medical Centre in Kinshasa. A questionnaire was developed containing the Urinary Symptom Profile (USP) scale. Kolmogorov-Smirnov normality tests were used to determine the normality of the distribution of the study variables. Inferential statistics were performed. The significance level was 0.05.
RESULTS: The mean age was 29.7±5.5 years. Thirty-eight women (29.9%) were primigravida. The median age of pregnancy was 6 weeks of amenorrhoea. The prevalence of urinary incontinence was 73.2%, with 31.2% of urge urinary incontinence and 16.1% of stress incontinence. In 61.4% of cases, overactive bladder was associated with urinary incontinence. Among the incontinent pregnant women, 3.2% had consulted a doctor while accepting that this condition is a health problem, 13.4% knew they had a pelvic floor muscle, 4.7% had knowledge of its rehabilitation, and 8.7% had benefited from gymnastics during pregnancy.
CONCLUSIONS: Urinary incontinence was frequent in the first trimester of pregnancy with a predominance of urgency. It was hardly discussed during prenatal consultations and pregnant women were not aware of the pelvic floor muscle, its rehabilitation, and of gymnastics during pregnancy.
Background: Chemodenervation is an important means of treating oral-ocular synkinesis, but upper eyelid treatment is avoided due to risk of blepharoptosis. Objective: To measure the change in eyelid position among patients with oral-ocular synkinesis who received botulinum toxin to the upper eyelid orbicularis oculi compared with those who received lateral and lower eyelid treatment alone. Methods: In this retrospective clinical study, patients were categorized as having received lateral and lower eyelid botulinum toxin alone or having received upper eyelid botulinum toxin (to the preseptal and orbital orbicularis oculi) along with lateral and lower eyelid treatment. Pre- and posttreatment margin to reflex distance 1 (MRD1), margin to reflex distance 2 (MRD2), and palpebral height were measured using Emotrics software and compared using t tests and regression analysis. Results: Twenty-five patients were included. Mean age was 48.7 years and 24% were male. Mean duration of paralysis was 29 months (range 9-360 months). Posttreatment resting MRD1 (3.36) was not significantly different than pretreatment resting MRD1 (3.43) for patients who received upper eyelid botulinum toxin (p value = 0.60). Conclusion: Botulinum toxin to the upper eyelid orbicularis oculi injected superficially in small, concentrated aliquots did not result in blepharoptosis and was effective in reducing oral-ocular synkinesis.
A nutraceutical composition comprises a cucumber (Cucumis sativus) extract, preferably for use in reducing TNF-Î± induced inflammation. Preferably the nutraceutical is formulated in a dose form to be administered orally. The nutraceutical preferably comprises between 5 to 200mg of raw extract. The nutraceutical may comprise a substance selected from the group consisting of silicon dioxide, cellulose, calcium phosphate or magnesium stearate. The nutraceutical may comprise a core containing the raw extract and an external layer wherein the external layer may be gastro-resistant layer. The external gastro-resistant layer may comprise: at least one substance selected from the group consisting of microcrystalline cellulose, saccharose, corn starch, lactose and/or mixtures thereof; or it may comprise polymers and/or copolymers of acrylic acid and/or methacrylic acids or salts; or it may comprise sodium carboxymethylcellulose. The raw cucumber extract can inhibit the production of TNF-Î± in human blood without causing adverse immune reactions and thus is useful as a nutraceutical or dietary supplement for a prolonged time in the prevention and treatment of TNF-Î± level dependent inflammation states.
The present invention relates to a method for preparing a Cirsium Japonicum extract enhancing NRF-2 activity and a cosmetic composition containing the same. More specifically, the method for preparing a Cirsium Japonicum extract enhancing NRF-2 activity comprises a step of extracting Cirsium Japonicum in a 75-99.5% ethanol solvent and a step of obtaining powder by depressurized-drying or frozen-drying the extracted Cirsium Japonicum extract. According to the present invention, loss of the main ingredients of the Cirsium Japonicum extract is minimized. The refined Cirsium Japonicum extract, prepared by a certain continuous process, is an active ingredient. As the Cirsium Japonicum extract, which increases activity of ARE protein associated with anti-oxidant protein Nrf-2, is applied to skin, homeostasis of skin, which is continuously exposed and suffers from stress, is maintained. The cosmetic composition has an excellent effect of preventing aging of skin caused by active oxygen.
HYPOTESIS: Total-face mask may improve the efficacy of NIV compared to conventional face mask in patients with acute respiratory failure due to enhanced tolerance and the allowance of higher airway pressure without massive leaks.OBJECTIVES: To assess, in acute respiratory failure patients, whether the total-face mask reduce the intubation rate. Additionally, whether it may improve mask tolerance, skin pressure damage, number of patients receiving higher pressures, or even a reduction in mortality. METHODS: 300 patients admitted in the ICU for acute respiratory failure needing continuous noninvasive mechanical ventilation. The type of mask (total-face vs. conventional face mask) will be randomized. PEEp will be titrated to the best oxygenation and IPAP up to reduce dyspnea and respiratory frequency, with the limits at clinical tolerance and massive leaks. Defined failure criteria and weaning technique will be used. Data to record include clinical parameters and mortality risk score (SAPS II), and physiologic response to NIV (either subjective and objective), technique failures and outcome. EXPECTED RESULTS: The study has been powered to detect a 30% relative improvement in intubation rate from a 35% baseline incidence of intubation in the conventional group.
The conventional therapies for HZ infection can be seen in two phases. Those in acute phase are mainly antiviral (acyclovir, famciclovir, etc.), analgesic drugs (opioids, acetaminophen or nonsteroidal anti-inflammatory agents, gabapentin, etc.), while these conventional drug therapies could yield potential side effects, and part of patients are not fully satisfied with the analgesic effect. It is considered that supplementary and alternative local therapies may have better results with less side effects and reduce medical costs to relieve pain associated with HZ infection. These options, including nerve blockade (epidural injection, paravertebral injection, sympathetic block, intercostal nerve block, intracutaneous injection), pulsed radiofrequency16, acupuncture, fire needling acupuncture, electrical nerve stimulation19, lidocaine patch, capsaicin cream, and botulinum toxin injection have been reported to give positive therapeutic effects on acute herpes zoster neuralgia (AHN), however, evidence for the efficacy of existing local therapies is limited and risks may occur due to high invasiveness of some procedures, there is insufficient evidence and expert agreement to make recommendations for these intervention strategies as first-line treatments in guidelines.
Renal Toxicity

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

No information is available from controlled clinical studies regarding the use of naproxen tablets in patients with advanced renal disease. The renal effects of naproxen tablets may hasten the progression of renal dysfunction in patients with preexisting renal disease.

Correct volume status in dehydrated or hypovolemic patients prior to initiating naproxen tablets. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of naproxen tablets [ see Drug Interactions (7)]. Avoid the use of naproxen in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If naproxen tablets is used in patients with advanced renal disease, monitor patients for signs of worsening renal function. 

Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.
The invention relates to the field of protein preparation and transdermal delivery, and discloses a method for preparing biologically active botulinum neurotoxin and a multilayer multiphase nanoparticle. The process comprises fermenting the bacterium botulinum in a fermentation medium free of animal derived components and contacting the fermentation medium with an anion exchange medium slurry and centrifuging to obtain a supernatant comprising botulinum neurotoxin. The method further comprises dialyzing the supernatant and collecting a dialyzed solution comprising botulinum neurotoxin, contacting the dialyzed solution with an anion exchange chromatography column, contacting an eluate collected from the anion exchange chromatography column with a cation exchange chromatography column, and collecting the eluate. The nanoparticles comprise an innermost aqueous phase core or an oil phase core, an aqueous phase layer, an oil phase layer and an outermost cream layer. The aqueous phase layer and the oil phase layer are alternately encapsulated to form a multi-layered multi-phase nano-cell particle. The biological molecules include active molecules such as botulinum neurotoxin and/or hyaluronic acid.
Neurological symptoms associated with COVID-19, acute and long term, suggest SARS-CoV-2 affects both the peripheral and central nervous systems (PNS/CNS). Although studies have shown olfactory and hematogenous invasion into the CNS, coinciding with neuroinflammation, little attention has been paid to susceptibility of the PNS to infection or to its contribution to CNS invasion. Here we show that sensory and autonomic neurons in the PNS are susceptible to productive infection with SARS-CoV-2 and outline physiological and molecular mechanisms mediating neuroinvasion. Our infection of K18-hACE2 mice, wild-type mice, and golden Syrian hamsters, as well as primary peripheral sensory and autonomic neuronal cultures, show viral RNA, proteins, and infectious virus in PNS neurons, satellite glial cells, and functionally connected CNS tissues. Additionally, we demonstrate, in vitro, that neuropilin-1 facilitates SARS-CoV-2 neuronal entry. SARS-CoV-2 rapidly invades the PNS prior to viremia, establishes a productive infection in peripheral neurons, and results in sensory symptoms often reported by COVID-19 patients.
The invention relates to a molecular marker penk and application thereof in a triple negative breast cancer drug, which are characterized in that the expression of penk in TNBC is remarkably reduced through Oncomine database collection and screening and qRT-PCR technology-based patient tissue sample inspection, the average reduction multiple in the database is 3.69, and the average reduction in the patient tissue sample is 98.05%. The reliability and repeatability of penk as a TNBC molecular marker are shown. The invention proves that penk obviously inhibits the proliferation, metastasis and invasion of TNBC cancer cells, and promotes cell cycle arrest and apoptosis, thereby influencing the development of tumors. The invention also proves the treatment effect of the penk overexpression system on TNBC tumors in animal bodies. The over-expression penk can obviously inhibit the growth of the tumor, the tumor inhibition rate is 37.5%, and tumor metastasis related factors, inflammatory factors and signal pathway related factors are obviously reduced. Histopathological analysis penk treatment resulted in significant necrosis of the tumor tissue. The results show that the penk drug has obvious treatment effect on TNBC tumors in animals.
Light developed by an implantable probe is used to illuminate a treatment site that has been perfused with a photoreactive agent. A number of different embodiments of implantable probes are disclosed. Preferably, an array of light emitting diodes (LEDs) or solid-state laser diodes (LDs) are mounted on a light bar inside the implantable probe and are energized either using a storage battery power source, an inductively coupled external transformer, or with current provided in leads running through a flexible catheter that extends outside the patient's body to an external source. The implantable probe is normally intended to be disposed inside a patient's body during a surgical procedure, at a treatment site, and left in place for several days (or longer) after an incision is closed, while light produced by the array of LEDs or solid-state LDs irradiates the treatment site. Alternatively, light from an external light source can be conveyed over one or more optical fibers to an implantable probe that is disposed inside the patient's body to irradiate the treatment site. Waste heat produced by the array of LEDs or LDs disposed on the implantable probe can be employed to augment the PDT by increasing the temperature of the tissue at the treatment site.
Experience in patients taking very high doses of pantoprazole is limited. There have been spontaneous reports of overdosage with pantoprazole, including a suicide in which pantoprazole 560 mg and undetermined amounts of chloroquine and zopiclone were also ingested. There have also been spontaneous reports of patients taking similar amounts of pantoprazole (400 mg and 600 mg) with no adverse effects.

Pantoprazole is not removed by hemodialysis. In case of overdosage, treatment should be symptomatic and supportive.

Single oral doses of pantoprazole at 709 mg/kg, 798 mg/kg, and 887 mg/kg were lethal to mice, rats, and dogs, respectively. The symptoms of acute toxicity were hypoactivity, ataxia, hunched sitting, limb-splay, lateral position, segregation, absence of ear reflex, and tremor.
The present invention relates to the fields of immunology and autoimmunity. More specifically, the invention provides methods and compositions relating to the production and use of antibodies to the pancreatic zinc transporter ZnT 8. The invention also provides an isolated antibody or antigen-binding fragment thereof that specifically binds to ZnT8, comprising a VH comprising the amino acid sequence of SEQ ID NO: 2. 12, 22, 32, 42 and 52. In an alternative embodiment, the isolated antibody or antigen-binding fragment thereof that specifically binds to ZnT8 comprises a VL comprising the amino acid sequence of SEQ ID NO: 7. 17, 27, 37, 47 and 57.
The invention relates to a biological paster for skin regeneration and maintenance. The biological paster has different release gradients and has the better skin regeneration and cosmetic effect. The biological paster is composed of two parts which are cooperated to be used. One part comprises a base and a plurality of micro needles located on the base. The other part comprises a back coating, namely a gel cold compress layer. A first soluble micro needle array and a second soluble micro needle array are arranged on the upper surface of the base and have different dissolution speeds. The first micro needle array comprises a plurality of first micro needles, and the second micro needle array comprises a plurality of second micro needles.
Matulane (procarbazine hydrochloride), a hydrazine derivative antineoplastic agent, is available as capsules containing the equivalent of 50 mg procarbazine as the hydrochloride. Each capsule also contains cornstarch, mannitol and talc. Gelatin capsule shells contain titanium dioxide, FD&C Yellow No. 6 and D&C Yellow No. 10.

Chemically, procarbazine hydrochloride is N‑isopropyl-∝-(2‑methylhydrazino)‑p‑toluamide monohydrochloride. It is a white to pale yellow crystalline powder which is soluble but unstable in water or aqueous solutions. The molecular weight of procarbazine hydrochloride is 257.76 and the structural formula is:
A delivery agent for delivering a biologically active agent to a warm-blooded animal includes a hydrophobic moiety covalently bonded to a hydrophilic moiety. The hydrophobic moiety can include bile acids, sterols, or hydrophobic small molecules. The hydrophilic moiety can include α-amino acids, dipeptides or tripeptides, or hydrophilic small molecules. An illustrative delivery agent is N α -deoxycholyl-L-lysine-methylester. The delivery agent and the biologically active agent are mixed together to form a complex, which is then administered to the animal. These complexes are particularly useful for oral administration of biologically active agents, but other routes of administration may be used.
A newly identified gene, DIS1 is disrupted by a (1;11)(q42.1;q14.3) translocation which segregates with schizophrenia. We have examined the genomic structure of DIS1 and found that the gene consists of 13 exons estimated to extend across at least 300kb of DNA. Exon 11 contains an alternative splice site which removes 66 nucleotides from the open reading frame. The final intron of DIS1 belongs to the rare AT-AC class of introns. 8 expressed sequence tags (ESTs) located within introns 3, 7, 9 and 10 of DIS1 have also been identified. These ESTs have not yet been assigned to DIS1 and may therefore represent further novel genes in the region.
Compositions of foods, vitamin and mineral supplements, topical or oral drugs, and cosmetic products containing a small peptide or peptides for slowing degradation, for example by transition metals. The peptides are di, tri, tetra-, and/or penta-peptides containing two or more aspartic acid residues. The degradation of several of the vitamin and other constituents vitamin-mineral supplements can be considerably slowed by composition incorporating such peptides, particularly if soluble (and thus bioavailable) forms of copper and/or iron are also present. The peptides can be hydrolyzed by the normal digestive process thus releasing bound metals. Multiple aspartate peptide(s) compositions with foods, topical or oral drugs, cosmetic, and hair care products can replace synthetic chelating preservative agents. Methods are also described to effectively slow degradation and preserve the above products using multiple aspartate peptides.
Use of the senseware armband alone program - The intervention for the SWA Alone group was the SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
AIM: To examine physical activity levels in association with metabolic health and estimate the stability of metabolically healthy obese (MHO) phenotypes over a 2-year period.
METHODS: In total, 2848 men and women from families at risk of the development of diabetes were recruited. Participants were classified as obese or non-obese and metabolic health was defined using five existing definitions. Physical activity was estimated with the International Physical Activity Questionnaire and pedometers.
RESULTS: Prevalence of the MHO phenotype varied among definitions (0% to 20.2%). Overall, the MHO were more active than the metabolically unhealthy obese (MUO). Daily sitting hours (odds ratio [OR] = 1.055, 95% confidence interval [CI]: 1.009-1.104) and daily steps (per 500; OR = 0.934, 95% CI: 0.896-0.973) were remarkable predictors of metabolic health in individuals with obesity; and likewise, in individuals without obesity. After 2 years, 44.1% of baseline MHO adults transitioned to MUO, while 84.0% of the MUO at baseline remained at the same phenotype. Although physical activity was not a major determinant in phenotype transitioning, daily steps were associated with the maintenance of metabolic health over time in the non-obese group.
CONCLUSION: A universally accepted definition for MHO is needed. Being physically active can contribute to a metabolically healthy profile even in the presence of obesity; still, MHO is a transient condition and physical activity alone may not be an adequate factor for its maintenance.